Keyphrases
1-year Survival
25%
Acute Myeloid Leukemia
25%
Adult Patients
25%
Adverse Cytogenetics
25%
Complete Remission
50%
Confidence Interval
50%
De Novo Acute Myeloid Leukemia
25%
Favorable Risk
25%
FLT3-ITD
25%
Genome Sequence Analysis
25%
HiDAC
100%
High-dose Cytarabine
100%
Induction Therapy
25%
Median Survival
50%
Metagenomic Next-generation Sequencing (mNGS)
25%
Mitoxantrone
100%
Molecular Signature
25%
Multivariate Analysis
25%
Mutational Status
25%
Nucleophosmin 1 (NPM1)
25%
Odds Ratio
50%
Primary Refractory
25%
Refractory Patients
25%
Relapsed or Refractory
100%
Relapsed or Refractory Acute Myeloid Leukemia
100%
Salvage Regimen
25%
Salvage Therapy
75%
Secondary Health Conditions
25%
Tumor Protein p53 (TP53)
25%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Cohort Analysis
25%
Cytarabine
100%
De Novo Acute Myeloid Leukemia
25%
Disease
25%
Drug Megadose
100%
Mitoxantrone
100%
Multivariate Analysis
25%
Next Generation Sequencing
50%
NPM1
25%
Odds Ratio
50%
Salvage Therapy
75%
Spontaneous Remission
25%
Survival Rate
25%
Biochemistry, Genetics and Molecular Biology
Cohort Study
16%
Cytarabine
100%
Cytogenetics
33%
Drug Megadose
100%
Multivariate Analysis
16%
Myeloid
100%
Next Generation Sequencing
33%
NPM1
16%
Survival Rate
16%